Biosafety

About the Committee

The IBBC has jurisdiction over research conducted at MUM according to the IBBC guidelines. The scope of these guidelines applies to the setting up of the IBCs and to activities and/or research involving LMO/rDNA materials that are conducted by members of MUM, sponsored by MUM and/or other parties, conducted using the facilities at MUM and materials stored at any of the facilities at MUM.

Scope of IBC authority

The IBBC reports to the Vice President of Monash University Malaysian Campus Research, of and to the NBB any significant problems with or non-compliance of the Biosafety Guidelines for Contained Use Activity of LMOs and any significant research-related accidents or illnesses.

Suspension of protocol approval for the possession or use of LMO/rDNA materials, and other bio-hazardous material, including research that is non-compliance or that such use or possession poses a threat to the health and safety of the community.

Responsibility:

  • MUM IBBC is responsible for assessing the biosafety containment level for research involving recombinant DNA and synthetic nucleic acid molecules.
  • IBBC also oversees research with other potentially hazardous biologics. IBC currently oversees:
    • Recombinant DNA and synthetic nucleic acid molecules (this includes human gene transfer studies)
    • Infectious agents
    • Biological toxins
    • Human-derived tissues, fluids, cells
    • Certain animal-derived tissues, fluids, cells
    • Nationally-regulated Select Agents, experiments with Dual Use Research of Concern potential
    • Research requiring BSL3 containment
  • Review and report to the Head of the organization and to the NBB any significant problems with or non-compliance of the Biosafety Guidelines for Contained Use Activity of LMOs and any significant research-related accidents or illnesses.

Biosafety in the context of of the Biosafety Act 2007

Biosafety is used to describe efforts to reduce and eliminate the potential risks resulting from modern biotechnology and its products.

The concept of biosafety encompasses a range of measures, policies and procedures for minimizing potential risks that modern biotechnology may pose to human, plant and animal health, the environment and biological diversity.

Biological and biomedical research offers tremendous opportunities for improving our understanding of biological mechanisms and processes and for targeting new and more effective therapies for devastating conditions. at the same time, however, this research involving recombinant DNA, Infectious agents, and other potentially hazardous biologics carries Inherent safety risks. Working at an appropriate biosafety containment level and with the appropriate safety precautions is essential for mitigating those risks.

The Institutional Biosafety Committee (IBBC) is an institutional committee created under the Biosafety Act 2007 Guidelines and its underlining Policies and procedures are to review research involving recombinant DNA and synthetic nucleic acid research. The IBC also reviews all research involving biohazardous materials and has overall oversight and responsibility for the Biosafety program at Monash University Malaysia.

References:

*Biosafety Act 2007http://www.biosafety.nre.gov.my to get a copy of the National  `Guidelines for IBC ‘
*MUM IBBC Policies & Procedures (in progress for review by members)
*List of Members and their expertise